<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384966</url>
  </required_header>
  <id_info>
    <org_study_id>ID-076A201</org_study_id>
    <secondary_id>2017-003332-36</secondary_id>
    <nct_id>NCT03384966</nct_id>
  </id_info>
  <brief_title>A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent&#xD;
      platelets from binding together when administered by an injection under the skin in the thigh&#xD;
      or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475)&#xD;
      works and if there is a difference if the drug is injected in the thigh or in the belly. This&#xD;
      study will also help to find out more about the safety of this new drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the pharmacodynamic (PD) and pharmacokinetic (PK) properties of selatogrel in&#xD;
      patients with atherosclerotic disease, the present study will be conducted in patients with&#xD;
      chronic coronary syndromes (CCS). Assessment in a population of patients with CCS allows&#xD;
      better control and stability of concomitant treatments, and therefore more accurate&#xD;
      characterization of the pharmacodynamic and pharmacokinetic profiles of selatogrel in the&#xD;
      presence of background antiplatelet therapies.&#xD;
&#xD;
      The study will have 3 periods: a screening period of up to 21 days prior to randomization, a&#xD;
      treatment period of 2 days from randomization (Day 1) to 24 hours post dose (Day 2), and a&#xD;
      follow-up period from Day 3 to the safety follow-up telephone call 28 to 35 days after single&#xD;
      administration of study drug (End-of-Study).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Actual">September 18, 2018</completion_date>
  <primary_completion_date type="Actual">August 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinding will apply to treatment (ACT-246475 vs placebo). The dose (8 mg vs 16 mg) will be single blinded (subject blinded). The site for the sub-cutaneous injection (thigh vs abdomen) will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation</measure>
    <time_frame>From 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
    <description>The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Selatogrel Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
    <description>The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection.&#xD;
The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
    <description>Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve of Selatogrel From Time Zero to 24 Hour Time Point (AUC0-24)</measure>
    <time_frame>Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours post-dose</time_frame>
    <description>The area under the plasma concentration-time curve is the integral of the concentration-time curve after subcutaneous injection of selatogrel.&#xD;
The plasma pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation by Site of Treatment Administration (Thigh or Abdomen)</measure>
    <time_frame>From 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
    <description>The inhibition of platelet aggregation based on the route of administration, i.e. whether the pharmacodynamic response was different if selatogrel was administered subcutaneously in the thigh or in the abdomen, was analyzed.&#xD;
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation - Sensitivity Analysis</measure>
    <time_frame>From 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
    <description>To assess the robustness of results for the pharmacodynamic response, the main analysis was repeated for the per protocol participants. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA)</measure>
    <time_frame>Pre-dose, and from 30 minutes after administration of the subcutaneous injection up to 8 hours</time_frame>
    <description>Light transmission aggregometry was used as complementary method to the VerifyNow® to evaluate the effect of selatogrel on platelet aggregation. Platelet aggregation was triggered by addition of Adenosine diphosphate (ADP) 20 µM (micromole per liter) and monitored over 6 minutes. Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with 20 µM ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA % reflects stronger platelet inhibition, whereas a higher MPA % reflects weaker inhibition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Bleeding Events</measure>
    <time_frame>From study treatment administration on Day 1 up to 48 hours</time_frame>
    <description>Treatment-emergent adverse events in the category &quot;Haemorrhage (excluding laboratory terms)&quot; were of special interest and their incidence listed below.&#xD;
The role of the Independent Safety Event Committee was to monitor unblinded safety data obtained in the study, with a specific focus on study-drug-related clinically relevant major bleeding events, occurring within 48 hours after dosing (i.e. the treatment period).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">346</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Selatogrel 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selatogrel 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selatogrel</intervention_name>
    <description>Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.</description>
    <arm_group_label>Selatogrel 8 mg</arm_group_label>
    <other_name>ACT-246475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for subcutaneous administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selatogrel</intervention_name>
    <description>Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.</description>
    <arm_group_label>Selatogrel 16 mg</arm_group_label>
    <other_name>ACT-246575</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent prior to any study-mandated procedure.&#xD;
&#xD;
          2. Male and female subjects aged from 18-85 years, inclusive.&#xD;
&#xD;
          3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and at&#xD;
             Visit 2 before randomization.&#xD;
&#xD;
          4. Stable Coronary artery disease (CAD) defined by the presence of any of the following&#xD;
             conditions:&#xD;
&#xD;
               1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.&#xD;
&#xD;
               2. Previously documented myocardial infarction occurring more than 3 months prior to&#xD;
                  randomization.&#xD;
&#xD;
          5. Antiplatelet background therapy stable for at least 1 month prior to randomization.&#xD;
&#xD;
          6. Body weight ≥ 40.0 kg (88.2 lbs).&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for&#xD;
             peripheral artery disease within 3 months prior to randomization.&#xD;
&#xD;
          2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to&#xD;
             randomization.&#xD;
&#xD;
          3. Active internal bleeding, or medical history of recent (&lt; 1 month) bleeding disorders&#xD;
             or conditions associated with high risk of bleeding (e.g., clotting disturbances,&#xD;
             gastrointestinal bleed, hemoptysis).&#xD;
&#xD;
          4. Hemoglobin ≤ 10 g/dL at screening.&#xD;
&#xD;
          5. Loss of at least 250 mL of blood within 3 months of screening.&#xD;
&#xD;
          6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior to&#xD;
             screening (Visit 1).&#xD;
&#xD;
          7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand&#xD;
             disease).&#xD;
&#xD;
          8. Pregnant or breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida (UF) Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Tampa - Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine - Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Cardiology</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital (New York)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Center for Thrombosis Research and Translational Medicine</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Herzzentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>40530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital - Cardiothoracic Department</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East &amp; North Hertfordshire NHS Trust - Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <zip>SG14AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>April 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2021</results_first_posted>
  <disposition_first_submitted>July 11, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 17, 2019</disposition_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03384966/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03384966/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between 24 Jan and 18 Sep 2018. Twenty sites in 8 countries screened 362 participants and 17 sites randomized 346 participants.</recruitment_details>
      <pre_assignment_details>Of the 16 participants not randomized: 9 were ineligible; 4 withdrew consent; 1 was lost to follow-up, 1 was not randomized based on the physician's decision and 1 didn't complete screening within the protocol-defined window.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Selatogrel 8 mg</title>
          <description>The study had 3 consecutive periods: the screening period, a treatment period and the follow-up period.&#xD;
A participant that met all inclusion criteria and none of the exclusion criteria was randomized.&#xD;
In the treatment period 8 mg of selatogrel (ACT-246475) was administered via a single subcutaneous injection either in the abdomen or the thigh.&#xD;
The follow-up period started on Day 3 and ended with the safety follow-up telephone call or visit (Day 35).</description>
        </group>
        <group group_id="P2">
          <title>Selatogrel 16 mg</title>
          <description>The study had 3 consecutive periods: the screening period, a treatment period and the follow-up period.&#xD;
A participant that met all inclusion criteria and none of the exclusion criteria was randomized.&#xD;
In the treatment period 16 mg of selatogrel (ACT-246475) was administered via a single subcutaneous injection either in the abdomen or the thigh.&#xD;
The follow-up period started on Day 3 and ended with the safety follow-up telephone call or visit (Day 35).</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>The study had 3 consecutive periods: the screening period, a treatment period and the follow-up period.&#xD;
A participant that met all inclusion criteria and none of the exclusion criteria was randomized.&#xD;
In the treatment period placebo matching selatogrel was administered via a single subcutaneous injection either in the abdomen or the thigh.&#xD;
The follow-up period started on Day 3 and ended with the safety follow-up telephone call or visit (Day 35).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized at End of Screening Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician decision due to adverse event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Thigh Administration</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Abdomen Administration</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
      <group_list>
        <group group_id="B1">
          <title>Selatogrel 8 mg</title>
          <description>Selatogrel (ACT-246475) 8 mg was administered as a single subcutaneous dose.</description>
        </group>
        <group group_id="B2">
          <title>Selatogrel 16 mg</title>
          <description>Selatogrel (ACT-246475) 16 mg was administered as a single subcutaneous dose.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo was administered as a single subcutaneous dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="116"/>
            <count group_id="B4" value="345"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Per-protocol set - all participants who complied with the protocol sufficiently to allow adequate estimation of the treatment effect (including availability of primary pharmacodynamic endpoint assessment and absence of protocol deviations that impact on the treatment effect).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-protocol analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="93"/>
                    <count group_id="B4" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Per-protocol set - all participants who complied with the protocol sufficiently to allow adequate estimation of the treatment effect (including availability of primary pharmacodynamic endpoint assessment and absence of protocol deviations that impact on the treatment effect).</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Full analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="9.4"/>
                    <measurement group_id="B2" value="65.2" spread="8.5"/>
                    <measurement group_id="B3" value="64.9" spread="9.1"/>
                    <measurement group_id="B4" value="65.0" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-protocol analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="93"/>
                    <count group_id="B4" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="9.7"/>
                    <measurement group_id="B2" value="65.3" spread="8.8"/>
                    <measurement group_id="B3" value="65.1" spread="9.2"/>
                    <measurement group_id="B4" value="64.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Per-protocol set - all participants who complied with the protocol sufficiently to allow adequate estimation of the treatment effect (including availability of primary pharmacodynamic endpoint assessment and absence of protocol deviations that impact on the treatment effect).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-protocol analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="93"/>
                    <count group_id="B4" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Per-protocol set - all participants who complied with the protocol sufficiently to allow adequate estimation of the treatment effect (including availability of primary pharmacodynamic endpoint assessment and absence of protocol deviations that impact on the treatment effect).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-protocol analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="93"/>
                    <count group_id="B4" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Per-protocol set - all participants who complied with the protocol sufficiently to allow adequate estimation of the treatment effect (including availability of primary pharmacodynamic endpoint assessment and absence of protocol deviations that impact on the treatment effect).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Full analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-protocol analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="93"/>
                    <count group_id="B4" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <population>Per-protocol set - all participants who complied with the protocol sufficiently to allow adequate estimation of the treatment effect (including availability of primary pharmacodynamic endpoint assessment and absence of protocol deviations that impact on the treatment effect).</population>
          <units>kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Full analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="116"/>
                    <count group_id="B4" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="5"/>
                    <measurement group_id="B2" value="29" spread="6"/>
                    <measurement group_id="B3" value="31" spread="5"/>
                    <measurement group_id="B4" value="30" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-protocol analysis set</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="93"/>
                    <count group_id="B4" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="5"/>
                    <measurement group_id="B2" value="29" spread="5"/>
                    <measurement group_id="B3" value="30" spread="5"/>
                    <measurement group_id="B4" value="29" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation</title>
        <description>The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
        <time_frame>From 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
        <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation</title>
          <description>The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
          <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
          <units>Count of participants (i.e., responders)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study aimed at assessing the efficacy of each selatogrel dose versus placebo. The proportion of responders for each of the two doses of selatogrel was compared to placebo.&#xD;
No imputation was considered for handling missing values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>A p-value significance level was set to 0.025, based on an overall Type-I error rate of 0.05 adjusted for multiple comparisons using a Bonferroni approach (two comparisons).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>58.9</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.4</ci_lower_limit>
            <ci_upper_limit>154.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study aimed at assessing the efficacy of each selatogrel dose versus placebo. The proportion of responders for each of the two doses of selatogrel was compared to placebo.&#xD;
No imputation was considered for handling missing values in the main analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>A p-value significance level was set to 0.025, based on an overall Type-I error rate of 0.05 adjusted for multiple comparisons using a Bonferroni approach (two comparisons).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>61.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.1</ci_lower_limit>
            <ci_upper_limit>162.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Selatogrel Plasma Concentration (Cmax)</title>
        <description>The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection.&#xD;
The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.</description>
        <time_frame>Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
        <population>Pharmacokinetic analysis set - all participants that had a selatogrel concentration measurement after administration of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Selatogrel Plasma Concentration (Cmax)</title>
          <description>The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection.&#xD;
The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.</description>
          <population>Pharmacokinetic analysis set - all participants that had a selatogrel concentration measurement after administration of study treatment.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" lower_limit="146" upper_limit="868"/>
                    <measurement group_id="O2" value="484" lower_limit="161" upper_limit="1030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)</title>
        <description>Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).</description>
        <time_frame>Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
        <population>Pharmacokinetic analysis set - all participants that had a selatogrel concentration measurement after administration of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)</title>
          <description>Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).</description>
          <population>Pharmacokinetic analysis set - all participants that had a selatogrel concentration measurement after administration of study treatment.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.38" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.23" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve of Selatogrel From Time Zero to 24 Hour Time Point (AUC0-24)</title>
        <description>The area under the plasma concentration-time curve is the integral of the concentration-time curve after subcutaneous injection of selatogrel.&#xD;
The plasma pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.</description>
        <time_frame>Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours post-dose</time_frame>
        <population>Pharmacokinetic analysis set - all participants that had a selatogrel concentration measurement after administration of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve of Selatogrel From Time Zero to 24 Hour Time Point (AUC0-24)</title>
          <description>The area under the plasma concentration-time curve is the integral of the concentration-time curve after subcutaneous injection of selatogrel.&#xD;
The plasma pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.</description>
          <population>Pharmacokinetic analysis set - all participants that had a selatogrel concentration measurement after administration of study treatment.</population>
          <units>hours*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="716" lower_limit="347" upper_limit="1425"/>
                    <measurement group_id="O2" value="1358" lower_limit="487" upper_limit="2758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation by Site of Treatment Administration (Thigh or Abdomen)</title>
        <description>The inhibition of platelet aggregation based on the route of administration, i.e. whether the pharmacodynamic response was different if selatogrel was administered subcutaneously in the thigh or in the abdomen, was analyzed.&#xD;
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
        <time_frame>From 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
        <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg (Thigh)</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 8 mg (Abdomen)</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O3">
            <title>Selatogrel 16 mg (Thigh)</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O4">
            <title>Selatogrel 16 mg (Abdomen)</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Thigh)</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Abdomen)</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation by Site of Treatment Administration (Thigh or Abdomen)</title>
          <description>The inhibition of platelet aggregation based on the route of administration, i.e. whether the pharmacodynamic response was different if selatogrel was administered subcutaneously in the thigh or in the abdomen, was analyzed.&#xD;
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
          <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
          <units>Count of participants (i.e., responders)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Logistic regression (Type III analysis)</non_inferiority_desc>
            <p_value>0.1915</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation - Sensitivity Analysis</title>
        <description>To assess the robustness of results for the pharmacodynamic response, the main analysis was repeated for the per protocol participants. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
        <time_frame>From 15 minutes after administration of the subcutaneous injection up to 24 hours</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation - Sensitivity Analysis</title>
          <description>To assess the robustness of results for the pharmacodynamic response, the main analysis was repeated for the per protocol participants. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a &quot;responder&quot;.</description>
          <population>Per-protocol set</population>
          <units>Count of participants (i.e., responders)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA)</title>
        <description>Light transmission aggregometry was used as complementary method to the VerifyNow® to evaluate the effect of selatogrel on platelet aggregation. Platelet aggregation was triggered by addition of Adenosine diphosphate (ADP) 20 µM (micromole per liter) and monitored over 6 minutes. Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with 20 µM ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA % reflects stronger platelet inhibition, whereas a higher MPA % reflects weaker inhibition.</description>
        <time_frame>Pre-dose, and from 30 minutes after administration of the subcutaneous injection up to 8 hours</time_frame>
        <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA)</title>
          <description>Light transmission aggregometry was used as complementary method to the VerifyNow® to evaluate the effect of selatogrel on platelet aggregation. Platelet aggregation was triggered by addition of Adenosine diphosphate (ADP) 20 µM (micromole per liter) and monitored over 6 minutes. Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with 20 µM ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA % reflects stronger platelet inhibition, whereas a higher MPA % reflects weaker inhibition.</description>
          <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
          <units>percent maximum platelet aggregation (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="29.79"/>
                    <measurement group_id="O2" value="62.4" spread="31.5"/>
                    <measurement group_id="O3" value="65.6" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="12.1"/>
                    <measurement group_id="O2" value="13.5" spread="11.9"/>
                    <measurement group_id="O3" value="65.3" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="14.1"/>
                    <measurement group_id="O2" value="15.8" spread="15.7"/>
                    <measurement group_id="O3" value="65.6" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="12.8"/>
                    <measurement group_id="O2" value="16.5" spread="14.5"/>
                    <measurement group_id="O3" value="63.0" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="25.5"/>
                    <measurement group_id="O2" value="32.1" spread="25.1"/>
                    <measurement group_id="O3" value="63.7" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Longitudinal analysis of the treatment effect, from start of treatment to 8 hours after injection.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>P-value significance level is set to 0.025, i.e. type I error (0.05) adjusted for multiplicity (2 comparisons) using a Bonferroni approach.</method_desc>
            <param_type>LS Mean difference with placebo</param_type>
            <param_value>-27.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.4</ci_lower_limit>
            <ci_upper_limit>-19.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Longitudinal analysis of the treatment effect, from start of treatment up to 8 hours after injection.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>P-value significance level is set to 0.025, i.e. type I error (0.05) adjusted for multiplicity (2 comparisons) using a Bonferroni approach</method_desc>
            <param_type>LS Mean difference with placebo</param_type>
            <param_value>-31.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.0</ci_lower_limit>
            <ci_upper_limit>-23.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Bleeding Events</title>
        <description>Treatment-emergent adverse events in the category &quot;Haemorrhage (excluding laboratory terms)&quot; were of special interest and their incidence listed below.&#xD;
The role of the Independent Safety Event Committee was to monitor unblinded safety data obtained in the study, with a specific focus on study-drug-related clinically relevant major bleeding events, occurring within 48 hours after dosing (i.e. the treatment period).</description>
        <time_frame>From study treatment administration on Day 1 up to 48 hours</time_frame>
        <population>The safety analysis set (SAF) included all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events</title>
          <description>Treatment-emergent adverse events in the category &quot;Haemorrhage (excluding laboratory terms)&quot; were of special interest and their incidence listed below.&#xD;
The role of the Independent Safety Event Committee was to monitor unblinded safety data obtained in the study, with a specific focus on study-drug-related clinically relevant major bleeding events, occurring within 48 hours after dosing (i.e. the treatment period).</description>
          <population>The safety analysis set (SAF) included all participants who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All participants with at least one &quot;bleeding event&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Trombolysis In Myocardial Infarction (TIMI) major events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with &quot;Bleeding event of moderate intensity&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with &quot;Bleeding event of mild intensity&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye contusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical device site bruise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mouth haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vessel puncture site bruise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vessel puncture site haematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Petechiae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Assessments of the Inhibition of Platelet Reactivity at Predefined Time Points</title>
        <description>The inhibition of platelet aggregation was determined using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). After single-dose administration the inhibition of platelet aggregation was measured at pre-defined timepoints to observe the platelet reactivity and aggregation over a 24-hour timeperiod. A lower PRU reflects lower platelet reactivity, whereas a higher PRU reflects higher platelet reactivity.</description>
        <time_frame>Pre-dose (baseline) up to 24 hours post-dose injection</time_frame>
        <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Selatogrel 8 mg</title>
            <description>Selatogrel 8 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O2">
            <title>Selatogrel 16 mg</title>
            <description>Selatogrel 16 mg was administered as a single subcutaneous dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo was administered as a single subcutaneous dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessments of the Inhibition of Platelet Reactivity at Predefined Time Points</title>
          <description>The inhibition of platelet aggregation was determined using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). After single-dose administration the inhibition of platelet aggregation was measured at pre-defined timepoints to observe the platelet reactivity and aggregation over a 24-hour timeperiod. A lower PRU reflects lower platelet reactivity, whereas a higher PRU reflects higher platelet reactivity.</description>
          <population>Full Analysis Set - all participants that were randomized and who had study treatment administered.</population>
          <units>P2Y12 reaction units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.1" lower_limit="142.9" upper_limit="169.3"/>
                    <measurement group_id="O2" value="156.2" lower_limit="142" upper_limit="170.5"/>
                    <measurement group_id="O3" value="155.2" lower_limit="141.9" upper_limit="168.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="5.3" upper_limit="14.9"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.6" upper_limit="6.4"/>
                    <measurement group_id="O3" value="163.3" lower_limit="149.5" upper_limit="177.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="3.6" upper_limit="12.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.4" upper_limit="7.2"/>
                    <measurement group_id="O3" value="162.2" lower_limit="147.9" upper_limit="176.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="4.5" upper_limit="14.8"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.6" upper_limit="4.5"/>
                    <measurement group_id="O3" value="161.8" lower_limit="148.6" upper_limit="175.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="7.0" upper_limit="17.8"/>
                    <measurement group_id="O2" value="5.7" lower_limit="3.7" upper_limit="7.6"/>
                    <measurement group_id="O3" value="162.0" lower_limit="148.5" upper_limit="175.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="22.9" upper_limit="37.3"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7.8" upper_limit="14.9"/>
                    <measurement group_id="O3" value="162.4" lower_limit="148.8" upper_limit="176.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" lower_limit="76.6" upper_limit="99.7"/>
                    <measurement group_id="O2" value="47.3" lower_limit="38.9" upper_limit="55.6"/>
                    <measurement group_id="O3" value="164.1" lower_limit="150.6" upper_limit="177.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.2" lower_limit="130.2" upper_limit="158.1"/>
                    <measurement group_id="O2" value="128.6" lower_limit="116.3" upper_limit="140.9"/>
                    <measurement group_id="O3" value="153.3" lower_limit="139.4" upper_limit="167.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded up to 35 days after the single subcutaneous selatogrel dose administration. Treatment period: Treatment emergent adverse events were those adverse events with onset and up to 48 hours after study treatment administration. The follow-up period started on Day 3 and ended with the safety follow-up telephone call 35 days after selatogrel administration. During the follow-up period the participants continued to be observed. No interventions were performed.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Period - Selatogrel 8 mg</title>
          <description>In the treatment period 8 mg of selatogrel was administered via a single subcutaneous injection either in the abdomen or the thigh.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Period - Selatogrel 16 mg</title>
          <description>In the treatment period 16 mg of selatogrel was administered via a single subcutaneous injection either in the abdomen or the thigh.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Period - Placebo</title>
          <description>In the treatment period placebo matching selatogrel was administered via a single subcutaneous injection either in the abdomen or the thigh.</description>
        </group>
        <group group_id="E4">
          <title>Follow-up Period - Selatogrel 8 mg</title>
          <description>Participants that had been administered a single subcutaneous injection containing 8 mg selatogrel in the treatment period were followed-up for adverse events after the treatment period. The follow-up period started on Day 3 and ended with a telephone call or visit on Day 35.</description>
        </group>
        <group group_id="E5">
          <title>Follow-up Period - Selatogrel 16 mg</title>
          <description>Participants that had been administered a single subcutaneous injection containing 16 mg selatogrel were followed-up for adverse events after the treatment period. The follow-up period started on Day 3 and ended with a telephone call or visit on Day 35.</description>
        </group>
        <group group_id="E6">
          <title>Follow-up Period - Placebo</title>
          <description>Participants that had been administered a single subcutaneous injection containing placebo matching selatogrel were followed-up for adverse events after the treatment period. The follow-up period started on Day 3 and ended with a telephone call or visit on Day 35.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Participant was hospitalized 26 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>Participant was hospitalized 12 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Myocardial infarctions</sub_title>
                <description>Participant was hospitalized 18 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Participant died 18 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>Participant died 18 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Participant was hospitalized 30 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <description>Participant was hospitalized 14 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Participant was hospitalized 12 days after study treatment administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Medical device site bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vessel puncture site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Chemical burns of eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>ECG P wave inverted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Blood was collected with phenylalanine-proline-arginine-chloromethyl ketone as anticoagulant. Any direct comparison of absolute PRU values obtained in this study with those published from studies of other P2Y12 inhibitors should take this into account.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Desk</name_or_title>
      <organization>Idorsia Pharmaceuticals Ltd.</organization>
      <phone>+41 588 441977</phone>
      <email>clinical-trials-disclosure@idorsia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

